Time to Viral Suppression is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin

被引：0
|
作者：
Sulkowski, Mark S. [1 ]
Fried, Michael W. [11 ]
Ozaras, Resat [3 ]
Isakov, Vasily [4 ]
Wyles, David L. [5 ]
Ferenci, Peter [6 ]
Feld, Jordan J. [7 ]
Calinas, Filipe [8 ]
Gschwantler, Michael [9 ]
King, Martin [10 ]
Baykal, Tolga [10 ]
Gane, Edward J. [2 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Auckland City Hosp, Liver Unit, Auckland, New Zealand
[3] Istanbul Univ, Istanbul, Turkey
[4] Russian Acad Med Sci, Inst Nutr, Moscow 109801, Russia
[5] Univ Calif San Diego, La Jolla, CA 92093 USA
[6] Univ Klin Fuer Innere Med III, Vienna, Austria
[7] Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada
[8] EPE Hosp St Antonio Capuchos, Ctr Hosp Lisboa Cent, Lisbon, Portugal
[9] Wilhelminenspital Stadt Wien, Vienna, Austria
[10] AbbVie, N Chicago, IL USA
[11] Univ N Carolina, Liver Program, Chapel Hill, NC USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1950
引用
收藏
页码：1144A / 1145A
页数：2
相关论文
共 50 条
  • [41] TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)
    Kowdley, Kris V.
    Poordad, Fred
    Trinh, Roger
    Hezode, Christophe
    Zeuzem, Stefan
    Agarwal, Kosh
    Shiffman, Mitchell L.
    Wedemeyer, Heiner
    Berg, Thomas
    Yoshida, Eric M.
    Forns, Xavier
    Lovell, Sandra S.
    DaSilva-Tillmann, Barbara
    Campbell, Andrew L.
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S903 - S903
  • [42] TURQUOISE-II: SVR12 RATES OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)
    Poordad, F.
    Hezode, C.
    Trinh, R.
    Kowdley, K. V.
    Zeuzem, S.
    Agarwal, K.
    Shiffman, M. L.
    Wedemeyer, H.
    Berg, T.
    Yoshida, E. M.
    Forns, X.
    Lovell, S. S.
    Da Silva-Tillmann, B.
    Campbell, A. L.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S523 - S523
  • [43] A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection
    Kowdley, Kris V.
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel E.
    Nelson, David R.
    Zeuzem, Stefan
    Everson, Gregory T.
    Kwo, Paul Y.
    Foster, Graham R.
    Sulkowski, Mark S.
    Xie, Wangang
    Pilot-Matias, Tami
    Liossis, George
    Larsen, Lois M.
    Khatri, Amit
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2012, 56 (06) : 1515 - 1516
  • [44] Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
    Eron, Joseph J.
    Lalezari, Jay
    Slim, Jihad
    Gathe, Joseph
    Ruane, Peter J.
    Wang, Chia
    Elion, Richard
    Blick, Gary
    Khatri, Amit
    Hu, Yiran B.
    Gibbons, Krystal
    Fredrick, Linda
    Co, Melannie
    D'Amico, Ronald
    Da Silva-Tillmann, Barbara
    Trinh, Roger
    Sulkowski, Mark S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 9 - 10
  • [45] 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin
    Jacobson, Ira M.
    Dufour, Jean-Francois
    Wedemeyer, Heiner
    Bernstein, David
    Colombo, Massimo
    Romero-Gomez, Manuel
    Reau, Nancy
    Trinh, Roger
    Xie, Wangang
    Enejosa, Jeffrey
    Cohen, Daniel
    Martinez, Marisol
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S850 - S851
  • [46] SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333+/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY
    Kowdley, K. V.
    Lawitz, E.
    Poordad, F.
    Cohen, D. E.
    Nelson, D.
    Zeuzem, S.
    Everson, G. T.
    Kwo, P.
    Foster, G. R.
    Sulkowski, M.
    Xie, W.
    Larsen, L.
    Khatri, A.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S2 - S2
  • [47] Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders
    Lawitz, Eric
    Hezode, Christophe
    Varunok, Peter
    Thuluvath, Paul J.
    Baykal, Tolga
    Kapoor, Mudra
    Lovell, Sandra S.
    Wang, Tianli
    Pilot-Matias, Tami
    Vilchez, Regis A.
    Bernstein, Barry
    HEPATOLOGY, 2013, 58 : 244A - 244A
  • [48] Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
    Poordad, Fred
    Agarwal, Kosh
    Younes, Ziad
    Cohen, Daniel
    Xie, Wangang
    Podsadecki, Thomas
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 608 - 610
  • [49] REAL-WORLD DATAON THE USE OF RIBAVIRIN WITH OMBITASVIR/PARITAPREVIR/R WITH OR WITHOUT DASABUVIR IN HCV GENOTYPE 1 OR 4-INFECTED PATIENTS FROM THE GERMAN HEPATITIS C REGISTRY
    Welzel, T. M.
    Buggisch, P.
    Berg, T.
    Stein, K.
    Hettinger, J.
    Kleine, H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S826 - S826
  • [50] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS
    Lawitz, E.
    Gaultier, I.
    Poordad, F.
    Cohen, D. E.
    Menon, R.
    Larsen, L. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S482 - S482
12345